Format

Send to

Choose Destination
Cancer Cell. 2008 Dec 9;14(6):423-4. doi: 10.1016/j.ccr.2008.11.005.

Kidney cancer: now available in a new flavor.

Author information

1
Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA. william_kaelin@dfci.harvard.edu

Abstract

The role of the von Hippel-Lindau tumor suppressor protein (pVHL) in kidney cancer has provided a rationale for treating this disease with hypoxia-inducible factor (HIF) antagonists. In this issue, Simon and coworkers show that the molecular signature of VHL(-/-) kidney cancers is profoundly influenced by whether they produce both HIF2alpha and HIF1alpha or HIF2alpha alone.

PMID:
19061830
DOI:
10.1016/j.ccr.2008.11.005
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center